use disorders

Prazosin hydrochloride (Vasoflex) reduces peripheral resistance and relaxes vascular smooth muscles as a selective adrenergic alpha-1 antagonist by a mechanism not completely known. Prazosin hydrochloride is a synthetic piperazine derivative with hypotensive antiadrenergic properties, It is used in the treatment of heart failure, hypertension, pheochromocytoma, Raynaud's syndrome, prostatic hypertrophy, and urinary retention.

(5R)-BW-4030W92, the active enantiomer of BW-4030W92, is an orally available, non-selective, voltage-dependent, and use-dependent sodium channel antagonist used in the study of neurological disorders.

Ipratropium bromide monohydrate (Ipratropium bromide hydrate) is a muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic.

Trans-Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. It was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.

SR-29065 is a selective REV-ERBα agonist that inhibits BMAL1 transcription within the circadian transcription–translation feedback loop, and it has been applied to evaluate whether targeting both negative regulatory limbs of circadian control yields synergistic anti-tumor effects in glioblastoma models, supporting its broader use in autoimmune disorder and circadian rhythm research.

Mitapivat (AG-348) hydrochloride is an orally active and selective allosteric activator of pyruvate kinase R (PK-R). It enhances the PK-R-catalyzed conversion of phosphoenolpyruvate to pyruvate, thereby promoting the glycolysis pathway, increasing ATP production in red blood cells, and decreasing 2,3-diphosphoglycerate (2,3-DPG) levels. Mitapivat hydrochloride is being investigated for potential use in the study of pyruvate kinase deficiency and other anemia-related disorders.

PLA2-IN-1 (Compound 7) is a potent and selective inhibitor of phospholipase A (PLA2) with an IC50 value of 1 nM. It effectively inhibits PLA2-induced coagulation disorders in vitro and shows potential for use as an antidote for snake bites caused by cobra venom.

σ1R-IN-1 ((R,R)-1a) is an effective σ-1R inhibitor with an IC50 of 110 nM. It shows promising potential for use in research related to neuropsychiatric disorders.

17-Hydroxypregnenolone sulfate sodium is a crucial intermediate product in the synthesis of adrenal and gonadal steroids with brain permeability. It acts as a precursor in the biosynthesis of steroid hormones [such as glucocorticoids, sex hormones]. This compound shows potential for use in research related to adrenal function development and neurosteroid-associated diseases [such as cognitive disorders, neurodegenerative diseases].

Dopamine D3 receptor ligand-6 (Compound 196476) is a selective antagonist of the dopamine D3 receptor (D3). It holds potential for research in substance use disorders, including opioid and psychostimulant addiction.

5-HT2A agonist 3 (Compound P-141) is a selective agonist of the 5-hydroxytryptamine 2A receptor (5-HT2A) with an EC50 value of 13.80 nM. It shows potential for use in research on mental disorders such as depression, post-traumatic stress disorder, obsessive-compulsive disorder, and other central nervous system-related conditions.

Dopamine D3 receptor antagonist-3 is a selective positive allosteric modulator-antagonist (PAM-antagonist) of the D3 dopamine receptor (D3R) that can cross the blood-brain barrier. It demonstrates antagonistic activity in D3R-mediated β-arrestin recruitment assays with an IC50 of 2.5 μM and Kb of 0.49 μM, and in D3R-mediated Go-BRET assays with an IC50 of 0.34 μM. Dopamine D3 receptor antagonist-3 is applicable for the study of neuropsychiatric disorders, including substance use disorders.

Desmopressin acetate is a synthetic replacement for vasopressin, which reduces urine production. Medical use of Desmopressin acetate includes: (a) bed wetting; (b) diabetes insipidus; (c) nighttime urination; (d) clotting disorders.

GPR52agonist-4 (Compound 65) is a highly selective modulator of the G protein-coupled receptor GPR52. It shows potential for use in research on neuropsychiatric disorders.

Methocinnamox (M-CAM) is a selective μ-opioid receptor (MOR) antagonist with a Ki of 0.6 nM, known for its long-lasting receptor binding. Its extended activity results from non-covalent attachment to the MOR orthosteric site, which leads to prolonged receptor blockade requiring new receptor synthesis for function restoration. Additionally, Methocinnamox reversibly antagonizes κ-opioid receptors (KOR) (Ki = 4.9 nM) and δ-opioid receptors (DOR) (Ki = 2.2 nM) without exhibiting intrinsic agonistic activity. This compound can be utilized for reversing and preventing opioid overdose and use disorders.

Lefelsiran sodium is a small interfering RNA that targets ALDH2 and is used in research on alcohol use disorders.

Ipsapirone, a pyrimidinylpiperazine ligand, is potent and specific for 5-HT1A receptors and has potential therapeutic use in affective disorders.

Octanoic Acid-13C is intended for use as an internal standard for the quantification of Octanoic Acid (T3946) by GC- or LC-MS. Octanoic acid is a medium-chain saturated fatty acid. It has been found in Teleme cheeses made from goat, ovine, or bovine milk.1 Octanoic acid is active against the bacteria S. mutans, S. gordonii, F. nucleatum, and P. gingivalis (IC80s = <125, <125, 1,403, and 2,294 μM, respectively).2 Levels of octanoic acid are increased in the plasma of patients with medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, an inborn error of fatty acid metabolism characterized by hypoketotic hypoglycemia, medium-chain dicarboxylic aciduria, and intolerance to fasting.3,4

AZ2 is a highly selective, active PI3Kγ inhibitor (pIC50=9.3) for use in inflammatory and immune disorders.

KQMEEEAVRLFIEWLKNGGPSSGAPPPS is a Exendin-4 peptide derivative. Exendin-4 is a pure GLP-1 receptor agonist. Exendin-4 peptide derivatives are structurally derived from Exendin-4 and may relates to dual GLP-1/glucagon receptor agonists. Their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake. These dual GLP-1/glucagon receptor agonists show reduced activity on the GIP receptor to reduce the risk of hypoglycemia[1]. [1]. US20150315260 A1

Ristocetin A, a glycopeptide related to vancomycin, is an antibiotic produced by the microorganism Nocardia lurida[1]. Ristocetin A is currently in clinical use to treat bacterial infections [1]. Ristocetin A is an antibiotic which can be used to treat staphylococcal infections. The side effects of ristocetin A include thrombocytopenia and platelet agglutination. Ristocetin A has been used in two assays: the ristocetin cofactor assay and the ristocetin-induced platelet aggregation assay. These two assays could be used to diagnosis the von Willebrand disease and other bleeding disorders [2, 3]. The structural features of Ristocetin A are similar to vancomycin.

Ipratropium Free Base is a muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic.

1. Curculigoside (Curculigoside A) can prevent bone loss , improve osteogenesis and inhibit osteoclastogenesis of hAFSCs, suggesting its potential use to regulate hAFSC osteogenic differentiation for treating bone disorders. 2. Curculigoside can promote calcium deposition and increase the levels of ALP and Runx2 in osteoblasts under oxidative stress via anti-oxidative character. 3. Curculigoside possesses potent antioxidant properties against oxidative stress insults. can protect endothelial cells against oxidative injury induced by H2O2, suggesting that this compound may constitute a promising intervention against cardiovascular disorders.

Ph-HTBA, a high-affinity, brain-penetrating modulator for CaMKIIα, exhibits a binding affinity with a Kd value of 757 nM. It holds potential for use in research related to ischemia and neurodegenerative disorders.